GEA, founded in 1881, is one of the world’s largest systems suppliers for the food, beverage and pharmaceutical sectors with more than 18.000 employees. Their portfolio includes machinery and plants as well as advanced process technology. Some of their core technologies within the pharma & healthcare department include continuous unit operations such as feeding, continuous blending, twin screw granulation and tableting. The company has pioneered continuous manufacturing in drug production and was the first supplier to provide and install a complete powder-to-tablet line.
GEA’s pharmaceutical technology test centers in Belgium, Denmark, Germany, the UK, the USA, Singapore, China and South Korea provide global technical support and know-how to the pharmaceutical industry.
Leading global professional services company, Cognizant, and the Centre of Excellence in Sustainable Pharmaceutical Engineering and Manufacturing (CESPE) have today announced a partnership which will accelerate the realization of innovative, sustainable, and agile developments in the pharmaceutical sector, at large scales.
The partnership will focus on knowledge sharing and prototyping ground-breaking ideas across various industry related topics, such as industry 4.0 and maximizing the value of Digital Twins in R&D and manufacturing by hybrid modelling, with use of the latest advanced analytical methods. Cognizant will also become a CESPE Industrial Member, joining the growing community where academic researchers and industrial partners are connected and where they can exchange information on sustainable pharmaceutical engineering and manufacturing at multiple levels.
Both Cognizant and CESPE’s main goal is to reinvent the pharmaceutical and biopharmaceutical industry: Cognizant as a technology partner and CESPE as complementary research center. CESPE is a multidisciplinary innovation accelerator hosted at Ghent University focusing on the sustainable development, design and optimization of both drug substance and drug product production platforms. Ghent University (UGent) is a top 100 university and one of the largest Belgian universities in the heart of Europe. It is an active partner in national and international educational, scientific, and industrial cooperation. CESPE’s ambition is to become the reference center in end-to-end (bio)pharmaceutical manufacturing in Europe. It accelerates the development of emerging production technologies to manufacture the medicines of the future in a sustainable, agile way. Cognizant implements, integrates, operationalizes, and scales such innovations within the life sciences industry, while contributing to similar ground-breaking innovative ideas with resourceful individuals working for Cognizant with various skills and rich domain knowledge. Conversely, CESPE can apply Cognizant’s patented technological solutions in examining and prototyping their own research.
“We at Cognizant are incredibly excited to partner with a leading institute like CESPE. Together, we are going to make significant strides in the development of technologies like digital twins in the pharmaceutical industry. This will make companies, and the overall industry, much more flexible and effective, thus stimulating innovation. We are proud to be doing our part to support the significant life sciences industry in Belgium, which has huge impact both locally and beyond.”
Gregory Verlinden, Associate Vice President of Analytics & AI at Cognizant
“We are actively looking for partnerships that endorse our core values. Cognizant’s complementary nature is exactly what we are looking for: a balanced collaboration with a reciprocal knowledge exchange. Our collaboration starts with the digital twin but can certainly expand later.”
Bram Bekaert, Operational Manager at CESPE
Find out more about Cognizant on their webpage: https://www.cognizant.com/
On September 15, we hosted our first conference on Manufacturing Innovations for a Sustainable (Bio)Pharmaceutical Industry. We were thrilled to have more than 120 participants from over 40 different companies, who were able to enjoy our diverse program with ample networking opportunities. If you couldn’t make it or would like to relive the day, have a look at our aftermovie to take in some of the innovative atmosphere we witnessed that day!
We are excited to announce that professor Hristo Svilenov has joined CESPE as an academic member. With the onboarding of prof. Svilenov, we further strengthen our capabilities in the field of biopharmaceutical manufacturing.
Hristo Svilenov is a professor of biopharmaceutical manufacturing technology and formulation in the Laboratory of General Biochemistry and Physical Pharmacy at Ghent University. Before moving to Ghent, he was postdoc with Prof. Johannes Buchner at the Technical University of Munich funded by a fellowship from the Peter und Traudl Engelhorn Foundation and a grant from the Else Kröner-Fresenius Foundation. From 2016 to 2019, he did his PhD sponsored by a Maria Skłodowska-Curie fellowship in the group of Prof. Gerhard Winter at the University of Munich. For his research, Dr. Svilenov received several prizes like the Carl Wilhelm Scheele Award from the German Pharmaceutical Society (DPhG) or the Abbvie Award for the best doctoral thesis. He is a pharmacist by training.
Hristo Svilenov is working on different aspects of the development, manufacturing, and formulation of biotherapeutics. A strong research focus is on the application of novel analytical techniques and biophysical methods to design better therapeutic proteins and formulations.
9h30 Welcome & conference opening Rik Van de Walle, Rector UGent
9h40 Introduction to CESPE Prof. Thomas De Beer, CESPE Director
10h00 Flanders R&D policies for better health and care – Towards Recovery Resilience Kathleen D’Hondt, Policy Analyst, Department Economy, Science and Innovation – Flemish Government
10h15 Keynote ‘Healthcare Innovation: the crossroads of HealthTech and the (bio)pharmaceutical ecosystem’ Ann Van Gysel, CEO Medvia
10h45 Break (posters & exhibition booths)
Chemical drug substance manufacturing of the future
11h05 Drug Substance Manufacturing in 2030 – adaptive, connected & sustainable Yves Vancleemput, Director Business Development, Janssen Pharmaceutica
11h20 The Future will flow, more and more in the pharmaceutical sector Prof. Chris Stevens, UGent
11h35 Design of Sustainable Pharmaceutical Processes with Artifcial Intelligence Maarten Dobbelaere, UGent
Biopharmaceuticals: a fast growing pipeline
11h50 Setting up a large scale clinical and commercial CAR-T manufacturing HUB in Ghent Birk Vanderweeën, General Manager Europe, Legend Biotech
13h25 Continuous manufacturing of antibodies: the inevitable step towards sustainable drug manufacturing Koen Dierckx, CEO SimAbs
13h40 Discovery and selection of therapeutic antibodies with drug-like properties Prof. Hristo Svilenov, UGent
13h55 An academic’s journey to spin-out commercialization of a new manufacturing technology: continuous pharmaceutical lyophilization Prof. Thomas De Beer, UGent & RheaVita
Towards efficient Drug Product Development & Controlled Manufacturing
14h10 Challenges and opportunities in drug product development Fanny Stauffer, Drug Product Expert, UCB
14h30 Linking material proporties to their behavior during processing Prof. Chris Vervaet, UGent
Process simulation & sustainable systems engineering as key element for future proof pharmaceutical manufacturing
14h45 Advanced process simulation for smart manufacturing process development, scale-up and operation Wim Audenaert, CEO & Co-founder AM-Team
15h00 Sustainability Assessment in the pharmaceutical sector dr. Lieselot Boone, UGent
15h15 Break (posters & exhibition booths)
(Bio)pharmaceutical manufacturing; staying ahead of what’s next
15h45 Panel discussion Ann Van Gysel, CEO Medvia Claire Skentelbery, Director General EuropaBio Yves Vancleemput, Director Business Development, Janssen Pharmaceutica Birk Vanderweeën, General Manager Europe, Legend Biotech Prof. Thomas De Beer, CESPE Director (moderation: Tineke Van hooland)
16h30 Pech Kucha presentations
Closing
17h45 Closing word Sofie Bracke, Executive Councillor for Economy, Port and Sports, City of Ghent
Wouter De Soete, Manager CESPE Christoph Portier, CESPE Operations Manager
Networking reception & Dinner
18h00 – 22h00 (posters & exhibition booths)
On this page you will find all the updates considering the program of our CESPE conference on Manufacturing Innovations for a Sustainable (Bio)Pharmaceutical Industry. At this event, there will be a mix of senior industry leaders, policy makers, academics and startups. There will be a variety of talks on chemical drug substance, drug product and biotech manufacturing, providing insights in both industrial and academic state-of-the-art. There will also be ample opportunities to network with all participants.
What’s in it for you? You will:
Have access to state-of-the-art science in the field of chemical drug substance, drug product and biotech manufacturing
Get to know groundbreaking and disruptive manufacturing technologies
Expand your professional network
Learn more about our new facilities planned at Tech Lane Ghent Science Park, including cleanrooms to handle potent APIs
Have the latest insights in the new Master in Pharmaceutical Engineering, unique in Flanders and launched in September ’22.
Have discussion opportunities with talented PhD and postdoctoral researchers through interactive poster sessions
Learn about access to young talent through various master thesis opportunities
We are excited to announce Dr. Ann Van Gysel as keynote speaker at our CESPE Conference on Manufacturing Innovations for a Sustainable (Bio)Pharmaceutical Industry on September 15th in Ghent! Dr. Van Gysel was recently appointed as CEO of the spearhead cluster MEDVIA. In her keynote, she will focus on the current trends in healthcare and the (bio)pharmaceutical landscape.
Ann Van Gysel has always been passionate about innovation in healthcare. She started out as a biologist and received her PhD in molecular biology from the University of Gent. She acquired post-graduate degrees in Business Management and Marketing and Communications. In 2009, she joined FlandersBio as Managing Director. During her three-year tenure, she doubled the number of members, putting Flanders on the international map as a one of the major biotech hubs. In 2011, Ann founded Turnstone Communications, a consultancy agency providing communications and marketing services to healthcare, life sciences and pharmaceutical organizations in Belgium and abroad. She was the founder of the digital life sciences news platform BioVox.eu, sharing Belgian innovations with national and international professionals. Since January 2022 she has been the CEO of MEDVIA, a public-private partnership founded by the Flemish Government to support innovation in healthcare focusing on biotech, medtech and digital health.
CESPE is pleased to announce its yearly conference on Thursday September 15, 2022 focusing on Manufacturing Innovations for a Sustainable (Bio)Pharmaceutical Industry. This event will cover both drug substance and drug product manufacturing innovations, demonstrating the position of Flanders and Belgium as global leaders in (bio)pharmaceutical manufacturing. During this physical event in Ghent, you will have the opportunity to network with our academic members, industrial partners and policy makers. Therefore, this event is perfectly suited for senior scientists, industrial decision makers and policy makers active within the ecosystem.
Stay tuned for more information on the program and registration!
2 PhD Positions to develop a Predictive Framework enabling Real-Time Release Testing in Solid Dosage Manufacturing
Overview
This PhD project aims to develop a knowledge-based predictive framework for dissolution testing to enable real-time release testing (RTRt) in solid dosage manufacturing. The research will be conducted in close cooperation with pharmaceutical companies and the UGent research accelerator Centre of Excellence in Sustainable Pharmaceutical Engineering and Manufacturing (CESPE). The research outcome will be published in important scientific journals.
Traditionally, RTRt frameworks are developed by individual companies and partnering research institutions leading to a costly and resource-intensive process. Moreover, the development requires a thorough process understanding as well as controls embedded in the production processes. In this project, a predictive framework for dissolution testing will be developed using material, process, and PAT data from continuous direct compression process. This project presents a unique opportunity to work at the academia-industry interface on a very important and relevant topic to the pharmaceutical industry. A range of formulations and knowledge from multiple pharmaceutical companies involved in the project will lead to development of a generic and better predictive framework enabling RTRt.
The project currently has two open positions for PhD candidates: a PhD project with an Experimental focus and a PhD project with a mathematical modeling focus. The researcher with an experimental focus will get an in-depth scientific understanding, hands-on experience of direct compression based manufacturing and gain expertise in practical aspects of dissolution test development applicable to an industrial working environment. The researcher with a modeling focus will apply different modeling approaches of developing in vitro predictive dissolution models based on product and process understanding. Hence, a predictive dissolution modeling framework will be developed to support product development within the space explored during formulation and process optimization and as surrogate tests in a regulatory filing towards RTRt.
Profiles
Experimental research focus:
Master’s degree in pharmaceutical sciences, physical chemistry, or a related discipline
Experience in dissolution testing of pharmaceutical dosage forms.
Experience with various analytical techniques (DSC, XRD, IR, TGA, DVS, HPLC).
Experience in multivariate data analysis is desirable.
Mathematical modeling research focus:
Master’s degree in bioengineering, chemical engineering, and process engineering or a related discipline
Experience with the development of numerical methods
Experience with mechanistic and data-driven modeling methodologies
Experience in Python and/or MATLAB is desirable.
Candidates must have a strong interest in both experiments and theoretical modeling
More information For further information, please contact:
You have to use the online application tool available here or by sending an email to Ashish.Kumar@UGent.be to provide your CV with names of three references, motivation letter and transcripts of your bachelor and master studies.
Application deadline and start date
The position is available immediately and will remain open until it is filled. While the start date is flexible, the target is to start from Feb 2022.
2 PhD positions in Pharmaceutical Manufacturing Innovation with Focus on Continuous Pharmaceutical Freeze-Drying
Overview
The general goal of these PhD research projects is to further innovate in a continuous freeze-drying technology for (bio)pharmaceuticals and explore its potential as an enabler for different pharmaceutical products.
Topic 1: The evaluation of different energy supply systems for the continuous & controlled (mechanistic based) freeze-drying of biopharmaceutical unit doses.
Topic 2: Continuous freeze-drying as an enabling technology for different types of pharmaceutical products (e.g., lipid nano-particle based products, highly concentrated protein formulations, vaccines, cold chain distributed products, etc.) The research projects may be conducted in close cooperation between Ghent University (Belgium) and pharmaceutical companies and equipment manufacturers. The PhD project will be executed in Ghent, Belgium. The research outcome will be published in important scientific journals.
Profile
Master’s degree in Pharmaceutical Drug Development, Industrial Pharmacy, Pharmaceutical Engineering, Bio-science Engineering, Chemical Engineering or a related discipline.
Experience with pharmaceutical technology is desirable.
Candidates must have a strong interest in biopharmaceutical product development manufacturing innovation, analysis and data-analysis.
Pharmaceutical Process Analytics & Technology research group (Ghent University) Faculty of Pharmaceutical Sciences Prof. Dr. T. De Beer – Thomas.DeBeer@UGent.be – +32-9-2648097
How to apply
Please send your CV with names of three references, motivation letter and transcripts of your bachelor and master studies to Thomas.DeBeer@UGent.be
Belgium has an excellent position in the development of new medicines. ‘To continue to play that leading role, we also need to focus on innovation in drug production,’ says Professor Thomas De Beer.
With the CESPE Innovation Accelerator, Ghent University offers an answer to the need for top research infrastructure for innovation in pharmaceutical production technology. This is necessary to further anchor Belgium’s leading position in the field of drug development research and to guarantee its production in our region.
Need for innovation in pharmaceutical production
‘If you look at pharmaceutical manufacturing innovation over the last decades, it hasn’t kept up with the speed of drug development. Innovation in the pharmaceutical sector primarily focuses on the development of medicines. But the increasing complexity of medicines and their supply needs also requires innovation in production technology,’ says Professor Thomas De Beer. He is director of CESPE, the Center of Excellence for Sustainable Pharmaceutical Engineering & Manufacturing at Ghent University, which is the basis of the new innovation accelerator for production technology in the pharmaceutical sector.
‘Innovation in the pharmaceutical sector primarily focuses on the development of medicines. But the increasing complexity of medicines and their supply needs also requires innovation in production technology.’ Professor Thomas De Beer.
‘Unlike other sectors in the manufacturing industry, pharmaceutical products are often developed before it is clear how they can be produced on a large scale in a competitive, sustainable and flexible way. By linking the development of a medicine at an early stage to the development of the production process, you shorten the lead time,’ explains Professor De Beer.
‘The Corona pandemic has also increased the need for agile production technologies. Just think of the supply of intermediate substances in the event of an abruptly rising demand or local production of critical medicines, and the associated cold chain distribution at -80°C of certain vaccines. This requires new technologies and we will research and develop them in the new CESPE center in collaboration with the industry,’ says Wouter De Soete, manager of CESPE at Ghent University.
Unique research infrastructure
The CESPE Innovation Accelerator will include cleanrooms, lab and office space as well as a (bio)pharmtech incubator. ‘This combination of research infrastructure in the field of production innovation is unique in Belgium. With this we make a huge difference, not only for academic research but also for industry,’ emphasizes Professor De Beer.
‘This research infrastructure in the field of production innovation is unique in Belgium. With this we make a huge difference, not only for academic research but also for industry.’ Professor De Beer.
There are strict requirements for the production of medicines. You have to create the right conditions for researchers and for the products you work with. Thanks to the modular and flexible layout of the cleanrooms and lab areas, large companies, start-ups and research institutions can perform tests and collaborate under optimal conditions. This is the only way to create the right environment for innovation.’
The center also provides the necessary space to accommodate spin-offs resulting from this innovative research. ‘We strongly believe that cross-fertilization between industry and academia will lead to innovative production technologies. In the field of production technology within the pharmaceutical sector, we want to become the reference point, both for research and training of the right profiles. For that reason, we will start with a new master in pharmaceutical engineering in the academic year 2022-2023. This combination of pharmaceutical and engineering skills is much needed in the sector to realize innovation. By focusing on that, we are firmly convinced that this will lead to new start-ups. We also want to offer them the necessary support in the CESPE center to start up and grow.’
‘The main goal of CESPE is to be the leading innovation hub in Europe for the end-to-end pharmaceutical production of tomorrow’s medicines,’ according to Wouter De Soete. ‘That means that we examine the entire drug production chain, from development to its supply to the market, and examine how we can model and optimize it as best as possible. For this we have to call on different expertise. Just think of experts in the field of big data, AI, automation and robotization, energy-efficient production,…’ According to De Soete, the center in Zwijnaarde will be a game changer for the pharmaceutical industry in Flanders, which will also provide a lot of jobs.
Ghent University
Centre of Excellence in Sustainable Pharmaceutical Engineering & Manufacturing
Faculty of Pharmaceutical Sciences
Campus Heymans
Ottergemsesteenweg 460
B-9000 Gent, Belgium
Christoph Portier is the Manager of the Centre of Excellence in Sustainable Pharmaceutical Engineering and Manufacturing (CESPE). He is responsible for setting up and managing strategic alliances, scouting collaboration and funding opportunities and development & commercialisation of the CESPE Innovation Accelerator & Incubator. He initially joined CESPE in 2021 as Project Manager, Operations, focussing on project portfolio management, supporting academic CESPE members during the project proposal phase, and facility management of the CESPE Innovation Accelerator. After obtaining his Master in Drug Development and Advanced Master in Industrial Pharmacy, he joined the Laboratory of Pharmaceutical Technology as PhD researcher. His PhD research, in collaboration with Janssen, focused on increased process and formulation understanding during continuous twin screw wet granulation and downstream processing. During his PhD, he was (co)author of 14 peer reviewed publications. Additionally, he is experienced in hot melt granulation, hot melt extrusion and development of nasal spray suspensions. He is also active as reviewer for Pharmaceutics.
An Van Den Bulcke holds a Ph.D in Chemistry (Polymer Synthesis) and has an industrial career in product development and R&D management. In 2011 she started as Business Developer at ChemTech, the Chemistry Business and Valorisation cluster at Ghent University.
As Senior Business Developer, dr. An Van Den Bulcke is responsible for the coordination and facilitation of commercialisation of new research findings to market-ready technologies and products, specifically for biomedical markets (pharma, biotech, diagnostics), personal care (cosmetics) and biomaterials markets. She is the focal point for industrial collaborations and builds a relevant network of life science companies interested in chemical expertise or novel (patented) technologies to boost their innovations. In this way, she is involved i.a.:
Managing the portfolio of collaborations with academic and industrial partners
Building and managing a strategic IP portfolio
Prospecting licensing opportunities and negotiating licensing deals
Creation of spin-off companies
Specialties: research & innovation management – technology transfer – project portfolio management – out-licensing – intellectual property – technology & business development
Ghent University
Faculty of Engineering and Architecture
Centre for Polymer and Material Technologies
Department of Materials, Textiles and Chemical Engineering
Technologiepark Zwijnaarde 130
B-9052 Gent, Belgium
Prof. Dr. Ludwig Cardon became Mechanical Engineer in 1988 and joined the University College of Ghent, Belgium since 1990. He received his Ph.D. degree in Engineering in 2006 from the Birmingham City University, UK. Since 2006, he is the head of the Centre for Polymer & Material Technologies CPMT and professor at the faculty of Applied Engineering Sciences of the University College of Ghent. He is co-founder of the rapid prototyping research group (RPT), now integrated in CPMT. His actual research interests mainly include high-tech polymer technology/processing and RPT for several applications such as technical parts, biobased polymers, micro moulding, bioengineering and biomedical applications.
Dieter Deforce received his MSc Degree in Pharmaceutical Sciences in 1994 from the University of Ghent, Belgium. In 1999 he received his PhD in Pharmaceutical Sciences from the same university. In 1999 he was awarded a BAEF (Belgian American Educational Foundation) fellowship for his post‐doctoral research in the University of California, San Diego, USA. In 2000 he was appointed a FWO (Fund for Scientific Research, Flanders) postdoctoral research fellowship.
Dieter Deforce became a professor at the University of Ghent in 2001; he was appointed as head of the Laboratory of Pharmaceutical Biotechnology at the Faculty of Pharmaceutical Sciences. From 2001 till 2016 he was also head of the forensic DNA‐analysis laboratory, which he founded at the University of Ghent, accredited and recognized by the Belgian government. He remains in the forensic field as dedicated DNA expert.
He is chair of the Belgian Medicines Committee, member of the Scientific Advise Working Party of the European Medicines Agency. He is also the director of the ProGenTomics platform of the University of Ghent, providing amongst others proteomics and mainly mass spectrometry based protein analytical tools to the research community. He is a partner in NXT‐GNT, a research consortium providing the research community next generation DNA‐sequencing. He is member of the board of directors of the VIB.
His research focuses on applying proteomics and genomics platforms (including Next Generation Sequencing) in the field of post translational protein modifications, stem cell development, prenatal genetic diagnosis, (auto‐)immunity and forensics and he is (co‐)author of over 350 scientific papers.
Ghent University
Faculty of Pharmaceutical Sciences
Laboratory of Pharmaceutical Process Analytical Technology
Campus Heymans
Ottergemsesteenweg 460
B-9000 Gent, Belgium
Prof. dr. ir. Ashish Kumar has been working in the field of Pharmaceuticals and biologics development since 2007 in both academic and industrial set-up. Before joining Ghent University, he worked as a Senior Process Engineer at the drug product development division of Janssen Pharmaceutica, Belgium. He obtained his Ph.D. from Ghent University in 2015, for research on the experimental and model-based analysis of twin-screw wet granulation for continuous solid-dosage manufacturing in pharmaceutical production. Before, he obtained a Professional Doctorate in Engineering as a Designer in Bioprocess Engineering from the Technical University of Delft in 2011, and worked for Janssen Pharmaceutica, in Leiden, The Netherlands and Dr. Reddy’s Laboratories in India. His research interests lie in the area of developing insights regarding constitutive mechanisms of various pharmaceutical processes by combining experimental and mechanistic modeling frameworks to provide innovative solutions. The Pharma Eng research group he leads focuses on the model-based design of pharmaceutical and biopharmaceutical manufacturing equipment and processes for innovative drug products.
Valérie Vanhoorne graduated in 2011 with great distinction as a pharmacist (Master of Science in Drug Development) from Ghent University (UGent) and started her PhD under supervision of Prof. Jean-Paul Remon and Prof. Chris Vervaet in the Laboratory of Pharmaceutical Technology (UGent). In 2016, she obtained her PhD in Pharmaceutical Sciences studying continuous agglomeration technologies. She continued working in the lab as a postdoctoral researcher focusing on innovative manufacturing processes for oral solid dosage forms. Initially, she worked as a postdoctoral researcher in close collaboration with Janssen Pharmaceutica (Belgium) on the development of predictive empirical models for continuous direct compression and platform formulations for continuous twin screw granulation. Later on, as doctor-assistant, she also worked on patient-tailored dosage forms and performed a research stay at the University of Düsseldorf working on roller compaction. Her current research line will focus on formulation and process development of continuous manufacturing processes and on personalization of dosage forms (via 3D-printing and multi-particulate dosage forms) to meet the needs of specific patient populations.
Experimental planning using (AI based) Optimal Design of Experiments (DOE)
Quality & Process control
Above statistical methods are applied to: – Monitoring, assessing stability and performance of production processes – Optimization and validation of measurement systems – Modeling of industrial processes, determining “Design Space” & optimal process parameter control ranges
The Laboratory of Pharmaceutical Biotechnology focusses on the analytical part of the two main biological large molecules: proteins and nucleic acids (DNA and RNA). Over the years we have gathered an extensive state of the art infrastructure and know-how for protein and proteome analysis, including high end mass spectrometry (ProGenTomics). On the genomics side a core facility with a strong focus on next generation sequencing technologies was created (nxtgnt). In order to manage and analyse the data we also have quite some bioinformatics expertise both in-house and available through collaborations.
Some topics of our research:
Diagnosis of infectious diseases (SARS-CoV-2) by qualitative and quantitative use of mass spectrometry of proteotypic peptides after immunobased enrichment.
Combining proteome analysis with histone proteome analysis, the latter focusses on identifying histone modifications in the context of epigenetic adaptations in stem and cancer cell development, potentially serving as biomarkers also as markers for developmental toxicity.
Analysis (genomics) and isolation of rare (single) cells.
Given the complexity and increasing diversity of products and technologies in (bio-)pharmaceuticals processing, it is clear that there will be no “one size fits all” solution for new process development and manufacturing requirements. The research in Pharmaceutical Engineering (PharmaEng) group involves development and application of a digital twin of equipment, processes, and the environment, where functions and properties are treated using various mechanistic frameworks. The research group aims to apply these digital twins to deliver solutions covering all the three aspects of pharmaceutical process development – product design, process design, and process improvement. Modeling frameworks based on first-principles such as DEM, FEM, CFD, and PBM in combination with kinetic, thermodynamic models will be used to design and optimize the system to deliver drug substances and products with desired physical properties.
Our research areas include both classical batch and continuous processing unit operations. Within these fields, we have an extensive expertise in following domains:
Process equipment design and optimization
Process and equipment scale-up
Detailed modeling of pharmaceutical processes for mechanistic insights
Advanced pharmaceutical manufacturing control strategy
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
